ISO 14971:2019 - Medical Devices Risk Management Professional Free Practice Test — 30 Questions

Question 1

Following the successful market introduction of a novel neurostimulator system, post-production surveillance data reveals a statistically significant increase in reports of unintended stimulation patterns, potentially linked to a subtle interaction between the device\'s firmware and a recently updated operating system on a widely used patient management tablet. The manufacturer decides to revise the firmware to mitigate this interaction. Which of the following actions is most aligned with the principles of ISO 14971:2019 regarding the integration of post-production information and design changes?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, re-evaluating all identified hazards, risks, and control measures in light of the firmware modification.

Question 2

A manufacturer of an implantable cardiac defibrillator (ICD) decides to update the device\'s firmware to improve battery efficiency. This firmware update is delivered wirelessly to existing devices. Following the update, a small number of reports emerge indicating an unexpected increase in the rate of lead dislodgement, a known but previously well-controlled hazard. According to ISO 14971:2019, what is the primary action the manufacturer must undertake in response to this information?

Accepted Answer

Re-evaluate the risk management file to assess the impact of the firmware update on the lead dislodgement hazard and any other associated risks.

Question 3

A manufacturer of a Class II diagnostic imaging system, initially cleared for use in adult patients, is seeking to expand its intended use to include pediatric patients. This expansion involves modifications to the software interface and the addition of specific calibration protocols tailored for younger subjects. Following the implementation of these changes, what is the most appropriate action regarding the device\'s risk management file, according to ISO 14971:2019?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, including hazard identification, risk analysis, risk evaluation, and risk control measures, to account for the new intended use and patient population.

Question 4

Following a significant software update to a Class II implantable cardiac monitor, the manufacturer is conducting its post-market risk management review. The update aimed to improve battery life and data transmission efficiency. Which of the following actions is most critical to ensure continued compliance with ISO 14971:2019 and patient safety in light of this modification?

Accepted Answer

Re-evaluate all identified hazards and associated risks, considering potential new hazards or changes in the severity or probability of occurrence of previously identified hazards due to the software update, and update the risk management file accordingly.

Question 5

A medical device manufacturer is developing a novel implantable cardiac monitor. During the initial design and development phase, the team has focused heavily on the technical specifications and clinical efficacy. However, they have not yet formally documented the overall strategy for managing risks associated with the device throughout its lifecycle, including how risks will be evaluated against predefined criteria, who is responsible for specific risk management tasks, and the planned verification of risk control measures. According to ISO 14971:2019, what is the most significant deficiency in their approach at this stage?

Accepted Answer

The absence of a documented risk management plan.

Question 6

A manufacturer of a novel implantable cardiac rhythm management device has been receiving an increasing number of post-market reports indicating a subtle, intermittent failure mode in a specific component, leading to a temporary loss of pacing. While the device\'s primary safety mechanisms have prevented immediate harm in these instances, the underlying cause has been traced to a material degradation phenomenon not anticipated during the initial risk assessment. Given this emergent information, what is the most critical and immediate step the manufacturer must undertake according to the principles of ISO 14971:2019?

Accepted Answer

Initiate a comprehensive re-evaluation of the device's risk management file, including hazard identification, risk analysis, and risk evaluation, to incorporate the newly identified failure mode and its potential consequences.

Question 7

A manufacturer of a novel implantable cardiac rhythm management device receives multiple reports from post-market surveillance indicating an unexpected failure mode leading to asynchronous pacing in a subset of patients. This failure mode was not identified during the initial risk analysis. According to ISO 14971:2019, what is the most appropriate immediate action for the manufacturer regarding their risk management process?

Accepted Answer

Initiate a comprehensive review of the entire risk management file, re-evaluating the risk analysis, risk evaluation, and risk control measures for the identified failure mode and its potential impact.

Question 8

Following the successful market release of a novel diagnostic imaging system, what is the primary objective of the risk management activities during the post-production phase, according to the principles outlined in ISO 14971:2019?

Accepted Answer

To monitor the device's performance in the field, gather user feedback, and manage risks that emerge or are identified after the device is in commercial distribution.

Question 9

A manufacturer of a novel implantable cardiac defibrillator (ICD) receives post-market surveillance data indicating a statistically significant increase in reports of lead dislodgement, a hazard previously identified with a low probability of occurrence. This dislodgement has, in several instances, led to a failure to deliver therapy and subsequent patient harm. The manufacturer has already implemented a risk control measure involving detailed surgical implantation guidelines. What is the most appropriate immediate action according to the principles of ISO 14971:2019?

Accepted Answer

Initiate a comprehensive review of the risk management file, specifically re-evaluating the identified hazard of lead dislodgement and the effectiveness of the current risk control measures.

Question 10

Following a significant software update to a Class II diagnostic imaging device, which action is most critical to ensure ongoing compliance with ISO 14971:2019 requirements for risk management?

Accepted Answer

Conduct a thorough re-evaluation of the entire risk management file, specifically focusing on hazards and risk control measures potentially affected by the software modifications, and update the file accordingly.

Question 11

A manufacturer of a Class III implantable cardiac defibrillator system receives post-production reports indicating a previously unrecognized failure mode that could lead to an unintended pacing inhibition under specific environmental conditions. This failure mode has been confirmed through independent laboratory testing and has a potential for severe patient harm. According to ISO 14971:2019, what is the most appropriate immediate action for the manufacturer to take regarding their risk management process for this device?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, including the risk analysis, risk evaluation, and risk control measures, to address the newly identified hazard.

Question 12

A manufacturer of a novel implantable cardiac rhythm management device receives post-market surveillance data indicating a pattern of unexpected device deactivation in a specific patient demographic, linked to a previously uncharacterized electromagnetic interference (EMI) susceptibility. This EMI source was not anticipated during the initial risk analysis. Which of the following actions most accurately reflects the required response according to ISO 14971:2019 for managing this emergent risk?

Accepted Answer

Update the risk management file to include the new hazard, reassess the risk analysis for this specific failure mode, and verify the effectiveness of any new or modified risk control measures, ensuring the risk management report reflects these changes.

Question 13

Following a significant software update to a Class II implantable cardiac pacemaker, which action is most critical to ensure ongoing compliance with ISO 14971:2019 and relevant regulatory frameworks like the EU MDR?

Accepted Answer

Conduct a comprehensive re-evaluation of the risk management file, specifically focusing on hazards introduced or altered by the software update and verifying the continued effectiveness of existing risk controls.

Question 14

A manufacturer of an implantable cardiac defibrillator receives post-market surveillance data indicating a novel failure mode, not previously identified during design, where a specific software anomaly can lead to an unintended pacing inhibition in a subset of patients. This anomaly has been linked to two reported serious adverse events, both resulting in syncope. What is the most appropriate immediate action according to ISO 14971:2019 principles for managing this newly discovered risk?

Accepted Answer

Update the risk management file to include the new hazard, re-evaluate associated risks, and determine if risk control measures need modification or implementation.

Question 15

Considering the lifecycle approach mandated by ISO 14971:2019 for medical devices, at what point in the product development continuum is the initiation of the risk management process most strategically aligned with the standard\'s principles for effective risk mitigation and control?

Accepted Answer

During the initial conceptualization and design phases of the medical device.

Question 16

Following the implementation of a new risk control measure for a Class II implantable device designed to mitigate the risk of unintended electrical stimulation, what is the primary subsequent action mandated by ISO 14971:2019 to ensure the continued safety and efficacy of the device?

Accepted Answer

Verify the effectiveness of the implemented risk control measure and re-evaluate the residual risk.

Question 17

A manufacturer of an implantable cardiac defibrillator receives reports from multiple healthcare facilities detailing an unexpected failure mode where the device\'s battery depletes significantly faster than predicted in a subset of patients, leading to premature replacement and potential loss of therapy. This observation was not identified during the initial risk analysis for the device. What is the most appropriate immediate action according to the principles of ISO 14971:2019?

Accepted Answer

Initiate a comprehensive review of the risk management file, reassessing the identified hazards, risk analysis, and risk evaluation based on this new information, and implement necessary risk control measures if residual risk is deemed unacceptable.

Question 18

A manufacturer of a novel implantable cardiac defibrillator (ICD) has successfully completed its initial design and risk analysis, leading to market approval. During the first year of post-market surveillance, a statistically significant increase in reports of lead dislodgement is observed, which was a low-probability hazard identified during the initial risk assessment. This new data suggests a higher probability of occurrence than initially estimated. According to ISO 14971:2019, what is the most appropriate action regarding the risk management file?

Accepted Answer

The risk management file must be reviewed and updated to incorporate the new findings regarding the lead dislodgement hazard and its associated risk controls.

Question 19

A manufacturer of an implantable cardiac pacemaker receives feedback from post-market surveillance indicating a potential for intermittent signal interference following a recent firmware update designed to enhance battery efficiency. The update was deployed remotely to devices already in the field. What is the most critical immediate action required by the manufacturer according to the principles of ISO 14971:2019 concerning this post-market event?

Accepted Answer

Initiate a thorough review and update of the risk management file to assess the impact of the firmware update on identified hazards and risk control measures.

Question 20

Considering the lifecycle approach mandated by ISO 14971:2019, at what point is a comprehensive review of the risk management process and the associated risk management file most critically indicated, beyond routine periodic checks?

Accepted Answer

Upon the introduction of any new information that could affect the risk assessment of the medical device.

Question 21

Following a significant software update to a Class II implantable cardiac defibrillator, which action is most aligned with the principles of ISO 14971:2019 for maintaining the device\'s risk management file?

Accepted Answer

Conduct a comprehensive review of the existing risk management file to assess the impact of the software update on identified hazards, risks, and the effectiveness of implemented risk control measures, updating the file as necessary.

Question 22

A manufacturer of a novel implantable cardiac defibrillator (ICD) receives post-market reports detailing an unexpected failure mode where the device\'s battery prematurely depletes under specific, albeit rare, environmental conditions not fully characterized during pre-market testing. This depletion leads to a loss of pacing function. What is the most appropriate immediate action according to the principles of ISO 14971:2019 for managing this newly identified risk?

Accepted Answer

Initiate a comprehensive review of the risk management file, updating the risk analysis to include the new hazard and its associated risks, and evaluating the adequacy of existing risk control measures or implementing new ones.

Question 23

A manufacturer of an implantable cardiac defibrillator receives post-market surveillance data indicating a rare but potentially severe failure mode where a specific software algorithm, previously deemed low risk due to its infrequent activation, now appears to be triggered more often than anticipated under certain environmental conditions not fully characterized during initial design validation. This triggers a need to revisit the risk management process. Which of the following actions most accurately reflects the requirements of ISO 14971:2019 in response to this new information?

Accepted Answer

Conduct a comprehensive review of the risk management file, re-evaluating the identified hazard, associated risks, and the effectiveness of existing risk control measures, and update the file accordingly.

Question 24

A manufacturer of an implantable cardiac defibrillator (ICD) receives post-market surveillance reports detailing an unexpected increase in the failure rate of a specific component responsible for energy delivery, leading to a higher-than-anticipated incidence of failed defibrillation attempts. This new data suggests that the previously assessed residual risk associated with this failure mode might now be unacceptable. What is the most appropriate immediate action according to the principles outlined in ISO 14971:2019?

Accepted Answer

Initiate a comprehensive review of the risk management file, re-evaluate the risk assessment for the identified failure mode, and determine if further risk control measures are necessary.

Question 25

Following a significant software update to a Class II implantable cardiac pacemaker, which action is most aligned with the principles and requirements of ISO 14971:2019 for maintaining the device\'s risk management file?

Accepted Answer

Conduct a comprehensive re-evaluation of all identified hazards and associated risks, updating the risk management file to reflect any new or modified risk control measures necessitated by the software changes.

Question 26

A manufacturer of a novel implantable cardiac rhythm management device, following its market release, receives several reports through pharmacovigilance channels detailing an unusual pattern of premature battery depletion, leading to unexpected device cessation. Analysis of these reports indicates a potential failure mode not fully characterized during the pre-market risk assessment. What is the most appropriate immediate action for the manufacturer, according to the principles outlined in ISO 14971:2019, to address this emerging safety concern?

Accepted Answer

Initiate a comprehensive review of the entire risk management file, re-evaluating all identified hazards and associated risk control measures in light of the new information, and determine if the residual risk remains acceptable.

Question 27

A manufacturer of a Class II implantable cardiac stimulator has received post-market surveillance reports indicating a statistically significant increase in the incidence of lead dislodgement within the first six months of implantation, a risk previously assessed as infrequent. This new data suggests the existing risk controls might be insufficient for this specific failure mode. What is the most appropriate action according to the principles of ISO 14971:2019 for managing this evolving risk profile?

Accepted Answer

Revise the risk management file to incorporate the new data, re-evaluate the risk associated with lead dislodgement, and implement updated risk control measures if deemed necessary.

Question 28

Following a significant software update to a Class II implantable cardiac monitor, which action is most critical to ensure ongoing compliance with ISO 14971:2019 and relevant regulatory requirements such as the EU MDR (Regulation (EU) 2017/745)?

Accepted Answer

Conduct a comprehensive review of the entire risk management file to assess the impact of the software update on identified hazards, risks, and the effectiveness of existing risk control measures, and update documentation accordingly.

Question 29

A manufacturer of an implantable cardiac rhythm management device, initially intended for adult patients with specific bradycardia conditions, plans to adapt its software and lead design to accommodate pediatric patients with a broader range of arrhythmias. This adaptation involves changes to pacing algorithms, lead material biocompatibility considerations for smaller vascular structures, and a revised user interface for pediatric caregivers. According to ISO 14971:2019, what is the most appropriate risk management action to take *before* the modified device is released for clinical trials in the pediatric population?

Accepted Answer

Conduct a complete re-evaluation of the risk management file, including hazard identification, risk analysis, risk evaluation, and the implementation of new or revised risk control measures for the modified device.

Question 30

A manufacturer of an implantable cardiac defibrillator receives post-market surveillance data indicating a novel failure mode, not previously identified during design, which has been linked to a critical adverse event in a small but statistically significant number of patients. What is the most appropriate immediate action within the framework of ISO 14971:2019 to address this situation?

Accepted Answer

Initiate a comprehensive review and update of the risk management file, including re-evaluation of identified hazards, risk analysis, and risk control measures based on this new information.

ISO 14971:2019 - Medical Devices Risk Management Professional Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 14971:2019 - Medical Devices Risk Management Professional Certification